Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though ...

Hims & Hers took a hit when the Food and Drug Administration (FDA) announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply.

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Their tight supply had allowed Hims & Hers and others to sell cheaper versions of Novo's semaglutide. Hims & Hers said in February it cannot guarantee to continue to sell compounded semaglutide ...